STOCK TITAN
  1. Home
  2. News
  3. CLLS

Monthly information on share capital and company voting rights

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Cellectis (CLLS) reports a total number of shares in the capital and voting rights as of January 31, 2024. The company's ISIN code is FR0010425595 and is listed on Euronext Growth. Media and investor relations contacts are provided for further information.
Positive
  • None.
Negative
  • None.

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Feb. 02, 2024 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares
in the capital		Total number of voting
rights
01/31/202471,751,20177,686,818

For further information on Cellectis, please contact:     

Media contact:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com

Investor Relations contacts:       

Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577  

Attachment


The ISIN code for Cellectis is FR0010425595.

Cellectis is listed on Euronext Growth.

As of January 31, 2024, Cellectis reported 71,751,201 shares in the capital and 77,686,818 voting rights.

The media contacts for Cellectis are Pascalyne Wilson and Patricia Sosa Navarro.

The investor relations contacts for Cellectis are Arthur Stril and Ashley R. Robinson.
Stock CLLS logo
Cellectis

NASDAQ:CLLS

CLLS Rankings

#3865 Ranked by Market Cap
#4900 Ranked by Stock Gains
N/A Ranked by Dividends

CLLS Latest News

Apr 22, 2024
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
Apr 10, 2024
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Apr 8, 2024
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
Apr 4, 2024
Monthly information on share capital and company voting rights
Mar 4, 2024
Monthly information on share capital and company voting rights

CLLS Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
France
Paris

About CLLS

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.